InvestorsHub Logo
Post# of 251526
Next 10
Followers 826
Posts 119431
Boards Moderated 16
Alias Born 09/05/2002

Re: DewDiligence post# 211130

Friday, 10/20/2017 11:36:40 AM

Friday, October 20, 2017 11:36:40 AM

Post# of 251526
DRRX -60% on phase-3 failure of Posimir in post-operative pain:

https://finance.yahoo.com/news/durect-announces-top-line-results-215700899.html

NVS licensed the US rights to Posimir in May 2017 (#msg-131156190) for $20M up-front.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.